You are viewing issue# 940

Cicilline outlines priorities for antitrust subcommittee if Dems win the House

Democrats have made stronger antitrust enforcement a key component of their campaign platform to try to win back control of the House in the mid-term elections. If they succeed, Representative David Cicilline, the top Democrat on the Judiciary Subcommittee on Regulatory Reform, Commercial and Antitrust Law, will be a leader in the debate over the direction of competition policy.

Read More

House Judiciary Committee to see leadership shift in 2019

The House panel that oversees antitrust policy will have a new leader next year regardless of which party controls the chamber.

Powers takes reins as DOJ top criminal antitrust enforcer amid questions

The appointment of Richard Powers as the Justice Department antitrust division's acting deputy for criminal enforcement has provoked some head scratching.  

FDA chief Gottlieb ‘names and shames’ big pharma for delaying generic competition

When Dr. Scott Gottlieb, commissioner of the Food and Drug Administration, publicly listed pharmaceutical companies that have “potentially blocked access” to samples of their branded products to...

Real estate mogul champions California privacy measure as tech battle brews

Over the past six months, Alastair Mactaggart has plowed $3.3 million of his own money into a California ballot initiative to pass the most extensive privacy and data security law in the United...

Uber official, others talk antitrust advocacy, regulation

It all depends on what the meaning of balanced is.

Neil Averitt commentary: New commissioners should study architecture of FTC Act

One of the keys to a successful Federal Trade Commission practice — whether as a new commissioner or as a lawyer appearing before the agency — is to understand the overall architecture of the FTC...

Appeals court rules FTC attorneys have immunity for roles in LabMD case

Bayer, Monsanto agree to $9 billion asset sale to win US clearance

Wilhelmsen-Drew Marine deal would cause estimated $14-23 million in harm, economist testifies for FTC